Evaluation of a Diagnostic Test to Identify the Best Drugs for Treatment of Metastatic Colorectal Cancer

Inclusion Criteria: * Willing and able to give written informed consent (for each part of the study) for participation in the clinical performance study. * Male or female patients, ≥18 years of age, with Eastern Cooperative Oncology Group (ECOG) performance status 0-1, who have metastatic lesions in the liver or peritoneum (or lymph nodes) that are radiologically assessable and can be biopsied, and who have recently failed 1st line systemic therapy (2nd line for patients with three standard therapy lines) for unresectable metastatic disease and will shortly commence a new line of standard therapy. * Patient is eligible for another line of tumour directed therapy on failure of the SoC. * Patient has the following laboratory values, as measured in serum/plasma within 14 days prior to signing of informed consent for participation in Part A and B, respectively, indicative of adequate organ function: * Haemoglobin at least 10.0 g/dL. * Neutrophils at least 1.5 x109/L (without current use of colony-stimulating factors). * Platelets at least 100 x109/L. * AST/ALT no higher than 2xULN when patient does not have metastatic disease in the liver, or no higher than 5xULN when patient has metastatic disease in the liver. * Bilirubin no higher than 1.5xULN when patient does not have metastatic disease in the liver, or no higher than 2xULN when patient has metastatic disease in the liver. * Albumin no lower than 30 g/L. * INR within normal level. * Creatinine no higher tha…